Novavax has celebrated the first shipment to Africa of its R21/Matrix-M malaria vaccine, developed in partnership with the Serum Institute of India (SII).

The vaccine, licensed for use in children in malaria-endemic regions, aims to bridge the gap between demand and available doses, with distribution in Africa scheduled to begin in the coming weeks.

The vaccine combines the malaria-specific R21 antigen with Novavax's Matrix-M adjuvant to boost the immune response.

Results from Phase 3 clinical trials published in February 2024 demonstrated 'its safety and efficacy', says the laboratory.

Copyright (c) 2024 All rights reserved.